Background: Medical questionnaires are important for assessing allergy patients. However, current methods of administering questionnaires are cumbersome, expensive, and laborious to accurately administer, track and score. eZhengtricity is a simple Google Documents based workflow, coupled with customized Excel formulas, that allow researchers to create, collect and score confidential health questionnaires that are globally accessible, with minimal setup time and maintenance. Methods: eZhengtricity utilizes a Google Documents account as a platform to create online questionnaires. Google automatically hosts the online questionnaire with a unique URL that can be provided to patients. The researcher provides patients with a unique study ID that is used to submit questionnaire responses. By using a unique study ID, researchers ensure confidentially of questionnaire data. Patient questionnaire responses are instantly submitted online to a secured "Cloud" database. In the Cloud database, the data is automatically sorted, scaled and scored by custom Excel formulas. Researchers can instantly access the database and download results in a variety of formats including PDF and XLS for further analysis using the researcher's statistical software of choice. Results: eZhengtricity provided questionnaire scores from submitted questionnaires instantly, while paper versions required manual double entry and manual sorting of patient data for analysis. Better overall quality of patient responses was obtained with eZhengtricity compared to paper questionnaires. Submitted responses to eZhengtricity had 100 percent completion while submitted paper responses had incomplete responses. Patient compliance for eZhengtricity was comparable to paper questionnaires. eZhengtricity also allowed monitoring of patient's progress on completing questionnaires. Conclusions: The flexibility and robustness of eZhengtricity complement longitudinal and cross-sectional studies. Compared to paper questionnaires, eZhengtricity is a cost effective, logistically easy, and superior way to administer confidential questionnaires. Background: Asthma remains a prevalent disease with significant morbidity and mortality, therefore numerous markers or measurements for the evaluation of its severity are available. Functional parameters, clinical assessment and biomarkers of inflammation are the most used. Also the diagnosis and treatment of asthma are often focused on young patients. This study was intended to determine the usefulness of patient-based questionnaire, Asthma Control Test score (ACT), forced expiratory volume in 1 second (FEV1) and exhaled nitric oxide (FeNO) for clinical assessment of elderly asthma patients. Patients and Methods: Sixty seven (67) patients with a diagnosis of asthma more than 65 of age were enrolled. They performed spirometry, FeNO measurement and answered the ACT questionnaire. ACT is scored on a scale from 5 to 25 with higher values reflecting better control. Spirometry measures that met the American Thoracic Society criteria were included. FeNO was measured with values $35 ppb indicating probability of airway inflammation. Qui-square test was used for statistical analysis. Results: 67 patients (15% female), mean age of 72.3 (65-89) were included. 25 patients (37.3%) were very poorly controlled, ACT # 15 and mean values of FEV1 81.5121.5 (% predicted) and mean FeNO of 41 6 35 ppb. Thirty patients (44.8%) were not-well-controlled, ACT 16 to 19, FEV1 89% 6 16.8, FeNO of 40 6 36 and 12 patients (17.9%) were well-controlled, ACT $ 20, FEV1 93.3 6 16.8 and FeNO of 44 6 35. FEV1 as .80% of predicted in 62.4% of patients (ACT 7-25) and 75% of patients with ACT $ 20 had FEV1 . 80%. The relation between ACT and FEV1 in this study was statistically significant (P ¼ 0.014). There was no correlation when we evaluated ACT/FeNO and FEV1/FeNo variables (P ¼ 0.45, 0.41 respectively). Conclusions: A good correlation was found between ACT and FEV1, with higher ACT scores reflecting less bronchial obstruction. FeNO values had no correlation with ACT or FEV1, indicating that this marker of inflammation had less interest for assessment of asthma control in these elderly patients. In spite of these data, we still advise that the clinical assessment of asthma should be based on a combined approach that involves clinical aspects, functional parameters and biomarkers of inflammation, because elderly patients may have reduced symptom perception and have multiple co-morbidity.
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Yong Ho Roh, MD, PhD. Pulmonary care, Seoul Veterans Hospital, Seoul, South Korea. Background: Asthma remains a prevalent disease with significant morbidity and mortality, therefore numerous markers or measurements for the evaluation of its severity are available. Functional parameters, clinical assessment and biomarkers of inflammation are the most used. Also the diagnosis and treatment of asthma are often focused on young patients. This study was intended to determine the usefulness of patient-based questionnaire, Asthma Control Test score (ACT), forced expiratory volume in 1 second (FEV1) and exhaled nitric oxide (FeNO) and 75% of patients with ACT $ 20 had FEV1 . 80%. The relation between ACT and FEV1 in this study was statistically significant (P ¼ 0.014). There was no correlation when we evaluated ACT/FeNO and FEV1/FeNo variables (P ¼ 0.45, 0.41 respectively). Conclusions: A good correlation was found between ACT and FEV1, with higher ACT scores reflecting less bronchial obstruction. FeNO values had no correlation with ACT or FEV1, indicating that this marker of inflammation had less interest for assessment of asthma control in these elderly patients. In spite of these data, we still advise that the clinical assessment of asthma should be based on a combined approach that involves clinical aspects, functional parameters and biomarkers of inflammation, because elderly patients may have reduced symptom perception and have multiple co-morbidity. 4 PharmIdeas Research and Consulting Inc., Ottawa, Ontario, Canada. Background: A systematic review of the literature was performed to gather all official recommendations on the prevention in infants of allergic manifestations (AM), and, more specifically, atopic dermatitis (AD), by using hydrolyzed infant formulas (HF) whether partially or extensively hydrolyzed (PHF; EHF). Methods: OVID MEDLINE and the grey literature were searched by 2 reviewers using the keywords AM, AD, prevention and guidelines. A third person acted as adjudicator in case of disagreement. Of interest were recommendations pertaining to the prevention of AM issued by national or regional associations of medical professionals. Results: This review yielded 11 sets of guidelines published for Australia, France, Germany, Spain, Switzerland (all n ¼ 1), Europe and the US (both n ¼ 3), 1999 to 2010. Most guidelines included AD either specifically (n ¼ 3) or within AMs. Most guidelines recommended a period of exclusive breastfeeding ranging from 4 to 6 months, and mentioned it as a major component of the primary prevention of allergic manifestations. Six guidelines (of which 2 recommended PHF over EHF) endorsed the use of HFs for the prevention of AM in "at risk" infants when exclusive breastfeeding was not or no longer possible. Two other publications did not recommend specific HFs, but formulas with documented reduced allergenicity. The need for an appropriate level of nutritional support was stressed in one publication. Five guidelines acknowledged that not all HFs have the same clinical protective benefit. Four publications underlined the importance of sound clinical evidence when determining the preventive efficacy of HFs and questioned the process leading to the development of national recommendations. None of the guidelines based their recommendations on recent evidence from meta-analyses of a specific brand of PHF. Conclusions: HFs, specifically PHFs, is endorsed for the prevention of AMs, but not consistently. The need for a strong validity of the clinical evidence is 
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